 | • レポートコード：MRC2204A150 • 出版社/出版日：Transparency Market Research / 2022年2月 • レポート形態：英文、PDF、151ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査レポートは、世界のファーマコビジランス（PV）市場について調査し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、医薬品開発フェーズ別（前臨床試験、フェーズI、フェーズII、フェーズIII、フェーズIV/市販直後調査）分析、方法別分析、サービス種類別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界のファーマコビジランス（PV）市場規模：医薬品開発フェーズ別（前臨床試験、フェーズI、フェーズII、フェーズIII、フェーズIV/市販直後調査） ・世界のファーマコビジランス（PV）市場規模：方法別 ・世界のファーマコビジランス（PV）市場規模：サービス種類別 ・世界のファーマコビジランス（PV）市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Pharmacovigilance Market – Scope of Report
TMR’s report on the global pharmacovigilance market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global pharmacovigilance market for the period 2017–2028, considering 2020 as the base year and 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global pharmacovigilance market during the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ literature, annual reports, press releases, and relevant documents to understand the global pharmacovigilance market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global pharmacovigilance market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global pharmacovigilance market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global pharmacovigilance market.
The report delves into the competition landscape of the global pharmacovigilance market. Key players operating in the global pharmacovigilance market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global pharmacovigilance market that have been profiled in this report.
Key Questions Answered in Pharmacovigilance Market Report
What is the scope of growth of phase of drug development companies in the global pharmacovigilance market?
What will be the Y-o-Y growth of the global pharmacovigilance market between 2019 and 2027?
What is the influence of changing trends in technologies on the global pharmacovigilance market?
Which region is likely to be the most profitable market for pharmacovigilance?
Which factors are anticipated to hamper the growth of the global pharmacovigilance market during the forecast period?
Which are the leading companies in the global pharmacovigilance market?
Research Methodology
A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global pharmacovigilance market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary methods referred to by analysts during the production of the global pharmacovigilance market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the pharmacovigilance market as primary methods.
These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the pharmacovigilance market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global pharmacovigilance market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global pharmacovigilance market more reliably and accurately.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pharmacovigilance Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pharmacovigilance Market Analysis and Forecast, 2017–2028
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. COVID-19 Impact on the Pharmacovigilance Market
5.2. Technological Advancements (big data analytics, cloud-based database, automation)
5.3. Drugs Regulatory Framework of Pharmacovigilance Market
5.4. Pharmacovigilance Market: Value Chain Analysis
5.5. Pharmacovigilance Market: Porter’s Five Forces Analysis
5.6. Overview of Drugs Adverse Effects
6. Global Pharmacovigilance Market Analysis and Forecast, by Phase of Drug Development
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Pharmacovigilance Market Value Forecast, by Phase of Drug Development, 2017–2028
6.2.1. Preclinical Studies
6.2.2. Phase I
6.2.3. Phase II
6.2.4. Phase III
6.2.5. Phase IV or Post Marketing Surveillance
6.3. Global Pharmacovigilance Market Attractiveness Analysis, by Phase of Drug Development, 2021-2028
7. Global Pharmacovigilance Market Analysis and Forecast, by Type of Method
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Global Pharmacovigilance Market Value Forecast, by Type of Method, 2017–2027
7.2.1. Spontaneous Reporting
7.2.2. Intensified ADR Reporting
7.2.3. Targeted Spontaneous Reporting
7.2.4. Cohort Event Monitoring
7.2.5. EHR Mining
7.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Method,2021-2028
8. Global Pharmacovigilance Market Analysis and Forecast, by Type of Service
8.1. Introduction & Definition
8.1.1. Key Findings / Developments
8.2. Global Pharmacovigilance Market Value Forecast, by Type of Service, 2017–2027
8.2.1. In-house
8.2.2. Contract Outsourcing
8.3. Global Pharmacovigilance Market Attractiveness Analysis, by Type of Service, 2021-2028
9. Global Pharmacovigilance Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Pharmacovigilance Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. North America Pharmacovigilance Market Attractiveness Analysis, by Region, 2021-2028
10. North America Pharmacovigilance Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027
10.2.1. Preclinical Studies
10.2.2. Phase I
10.2.3. Phase II
10.2.4. Phase III
10.2.5. Phase IV or Post Marketing Surveillance
10.3. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027
10.3.1. Spontaneous Reporting
10.3.2. Intensified ADR Reporting
10.3.3. Targeted Spontaneous Reporting
10.3.4. Cohort Event Monitoring
10.3.5. EHR Mining Others
10.4. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027
10.4.1. In-house
10.4.2. Contract Outsourcing
10.5. North America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. North America Pharmacovigilance Market Attractiveness Analysis, 2021-2028
10.6.1. By Phase of Drug Development
10.6.2. By Type of Method
10.6.3. By Type of Service
10.6.4. By Country
11. Europe Pharmacovigilance Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027
11.2.1. Preclinical Studies
11.2.2. Phase I
11.2.3. Phase II
11.2.4. Phase III
11.2.5. Phase IV or Post Marketing Surveillance
11.3. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027
11.3.1. Spontaneous Reporting
11.3.2. Intensified ADR Reporting
11.3.3. Targeted Spontaneous Reporting
11.3.4. Cohort Event Monitoring
11.3.5. EHR Mining
11.4. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027
11.4.1. In-house
11.4.2. Contract Outsourcing
11.5. Europe Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Pharmacovigilance Market Attractiveness Analysis, 2021-2028
11.6.1. By Phase of Drug Development
11.6.2. By Type of Method
11.6.3. By Type of Service
11.6.4. By Country/Sub-region
12. Asia Pacific Pharmacovigilance Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027
12.2.1. Preclinical Studies
12.2.2. Phase I
12.2.3. Phase II
12.2.4. Phase III
12.2.5. Phase IV or Post Marketing Surveillance
12.3. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027
12.3.1. Spontaneous Reporting
12.3.2. Intensified ADR Reporting
12.3.3. Targeted Spontaneous Reporting
12.3.4. Cohort Event Monitoring
12.3.5. EHR Mining
12.4. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027
12.4.1. In-house
12.4.2. Contract Outsourcing
12.5. Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Pharmacovigilance Market Attractiveness Analysis, 2021-2028
12.6.1. By Phase of Drug Development
12.6.2. By Type of Method
12.6.3. By Type of Service
12.6.4. By Country/Sub-region
13. Latin America Pharmacovigilance Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027
13.2.1. Preclinical Studies
13.2.2. Phase I
13.2.3. Phase II
13.2.4. Phase III
13.2.5. Phase IV or Post Marketing Surveillance
13.3. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027
13.3.1. Spontaneous Reporting
13.3.2. Intensified ADR Reporting
13.3.3. Targeted Spontaneous Reporting
13.3.4. Cohort Event Monitoring
13.3.5. EHR Mining
13.4. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027
13.4.1. In-house
13.4.2. Contract Outsourcing
13.5. Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Pharmacovigilance Market Attractiveness Analysis, 2021-2028
13.6.1. By Phase of Drug Development
13.6.2. By Type of Method
13.6.3. By Type of Service
13.6.4. By Country/Sub-region
14. Middle East & Africa Pharmacovigilance Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Phase of Drug Development, 2017–2027
14.2.1. Preclinical Studies
14.2.2. Phase I
14.2.3. Phase II
14.2.4. Phase III
14.2.5. Phase IV or Post Marketing Surveillance
14.3. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Method, 2017–2027
14.3.1. Spontaneous Reporting
14.3.2. Intensified ADR Reporting
14.3.3. Targeted Spontaneous Reporting
14.3.4. Cohort Event Monitoring
14.3.5. EHR Mining
14.4. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Type of Service, 2017–2027
14.4.1. In-house
14.4.2. Contract Outsourcing
14.5. Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, 2021-2028
14.6.1. By Phase of Drug Development
14.6.2. By Type of Method
14.6.3. By Type of Service
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share / Position Analysis, by Company, 2020
15.3. Competitive Business Strategies
15.4. Company Profiles
15.4.1. Accenture plc
15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.1.2. Phase of Drug Development Portfolio
15.4.1.3. Financial Overview
15.4.1.4. Strategic Overview
15.4.1.5. SWOT Analysis
15.4.2. Bristol-Myers Squibb
15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.2.2. Phase of Drug Development Portfolio
15.4.2.3. Financial Overview
15.4.2.4. Strategic Overview
15.4.2.5. SWOT Analysis
15.4.3. Clinquest Group B.V.
15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.3.2. Phase of Drug Development Portfolio
15.4.3.3. Financial Overview
15.4.3.4. Strategic Overview
15.4.3.5. SWOT Analysis
15.4.4. Cognizant
15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.4.2. Phase of Drug Development Portfolio
15.4.4.3. Financial Overview
15.4.4.4. Strategic Overview
15.4.4.5. SWOT Analysis
15.4.5. Labcorp Drug Development
15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.5.2. Phase of Drug Development Portfolio
15.4.5.3. Financial Overview
15.4.5.4. Strategic Overview
15.4.5.5. SWOT Analysis
15.4.6. F. Hoffmann-La Roche Ltd.
15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.6.2. Phase of Drug Development Portfolio
15.4.6.3. Financial Overview
15.4.6.4. Strategic Overview
15.4.6.5. SWOT Analysis
15.4.7. GlaxoSmithKline plc
15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.7.2. Phase of Drug Development Portfolio
15.4.7.3. Financial Overview
15.4.7.4. Strategic Overview
15.4.7.5. SWOT Analysis
15.4.8. ICON plc
15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.8.2. Phase of Drug Development Portfolio
15.4.8.3. Financial Overview
15.4.8.4. Strategic Overview
15.4.8.5. SWOT Analysis
15.4.9. iGATE Corporation
15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.9.2. Phase of Drug Development Portfolio
15.4.9.3. Financial Overview
15.4.9.4. Strategic Overview
15.4.9.5. SWOT Analysis
15.4.10. iMEDGlobal Corporation
15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.10.2. Phase of Drug Development Portfolio
15.4.10.3. Strategic Overview
15.4.10.4. SWOT Analysis
15.4.11. Syneos Health
15.4.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.11.2. Phase of Drug Development Portfolio
15.4.11.3. Financial Overview
15.4.11.4. Strategic Overview
15.4.11.5. SWOT Analysis
15.4.12. Novartis AG
15.4.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.12.2. Phase of Drug Development Portfolio
15.4.12.3. Financial Overview
15.4.12.4. Strategic Overview
15.4.12.5. SWOT Analysis
15.4.13. PAREXEL International Corporation
15.4.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.13.2. Phase of Drug Development Portfolio
15.4.13.3. Financial Overview
15.4.13.4. Strategic Overview
15.4.13.5. SWOT Analysis
15.4.14. Pfizer, Inc.
15.4.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.14.2. Phase of Drug Development Portfolio
15.4.14.3. Financial Overview
15.4.14.4. Strategic Overview
15.4.14.5. SWOT Analysis
15.4.15. Pharmaceutical Phase of Drug Development, LLC. (PPD)
15.4.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.15.2. Phase of Drug Development Portfolio
15.4.15.3. Financial Overview
15.4.15.4. Strategic Overview
15.4.15.5. SWOT Analysis
15.4.16. IQVIA
15.4.16.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.16.2. Phase of Drug Development Portfolio
15.4.16.3. Financial Overview
15.4.16.4. Strategic Overview
15.4.16.5. SWOT Analysis
15.4.17. Sanofi
15.4.17.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.17.2. Phase of Drug Development Portfolio
15.4.17.3. Financial Overview
15.4.17.4. Strategic Overview
15.4.17.5. SWOT Analysis
15.4.18. Synowledge LLC
15.4.18.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.18.2. Phase of Drug Development Portfolio
15.4.18.3. Strategic Overview
15.4.18.4. SWOT Analysis
15.4.19. Wipro Limited
15.4.19.1. Company Overview (HQ, Business Segments, Employee Strength)
15.4.19.2. Phase of Drug Development Portfolio
15.4.19.3. Financial Overview
15.4.19.4. Strategic Overview
15.4.19.5. SWOT Analysis
Table 01: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 02: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 03: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 04: Global Pharmacovigilance Market Size (US$ Mn) Forecast, by Region, 2017–2028
Table 05: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 06: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 07: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 08: North America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country, 2017–2028
Table 09: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 10: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 11: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 12: Europe Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 13: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 14: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 15: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 16: Asia Pacific Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 17: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 18: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 19: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 20: Latin America Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 21: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Phase of Drug Development, 2017–2028
Table 22: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Method, 2017–2028
Table 23: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Type of Service, 2017–2028
Table 24: Middle East & Africa Pharmacovigilance Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028